Effects of aflibercept on primary RPE cells: Toxicity, wound healing, uptake and phagocytosis

British Journal of Ophthalmology

Volumn 98, Issue 10, 2014, Pages 1448-1452

  Klettner, Alexa ^a   Tahmaz, Nihat ^a   Dithmer, Michaela ^a   Richert, Elisabeth ^a   Roider, Johann ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; COLORING AGENT; HYBRID PROTEIN; MICROSPHERE; MONOCLONAL ANTIBODY; RANIBIZUMAB; TRYPAN BLUE; VASCULOTROPIN RECEPTOR;

ADVERSE OUTCOME; ANIMAL CELL; ARTICLE; CELL TRANSPORT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; IMMUNOCYTOCHEMISTRY; INTRACELLULAR SIGNALING; MTT ASSAY; NONHUMAN; PHAGOCYTOSIS; PIGMENT EPITHELIUM; SWINE; TRYPAN BLUE ASSAY; WOUND HEALING; WOUND HEALING IMPAIRMENT; ANIMAL; CELL CULTURE; CELL MOTION; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PATHOLOGY; PHARMACOLOGY; RETINA;

PHARMACOLOGY; RETINA; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; COLORING AGENTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MICROSPHERES; PHAGOCYTOSIS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; SWINE; TRYPAN BLUE; WOUND HEALING;

EID: 84908267541     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305105     Document Type: Article

References (27)

1. Velez-Montoya R, Oliver SCN, Olson JL, et al. Current knowledge and trends in age-related macular degeneration. Today's and futures treatments. Retina 2013;33:1487-502.
2. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
3. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
4. Jyothi S, Chowdhury H, Elagouz M, et al. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye 2010;24:816-24.
5. Harding SP. Neovascular age-related macular degeneration: decision making and optimal management. Eye 2010;24:497-505.
6. Hörster R, Ristau T, Sadda SR, et al. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011;249:645-52.
7. Klettner A, Roider J. Treating age-related macular degeneration-interaction of VEGF-antagonists with their target. Mini Rev Med Chem 2009;9:1127-35.
8. Klettner AK, Kruse ML, Meyer T, et al. Different properties of VEGF-antagonists: Bevacizumab but not ranibizumab accumulates in RPE cells. Graefes Arch Clin Exp Ophthalmol 2009;247:1601-8.
9. Klettner A, Möhle F, Roider J. Intracellular bevacizumab reduces phagocytotic uptake in RPE cells. Graefes Arch Clin Exp Ophthalmol 2010;248:819-24.
10. Deissler HL, Deissler H, Lang GE. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences. Br J Ophthalmol 2012;96:1023-8.
11. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008;49:4523-7.
12. Hillenkamp J, Dydykina S, Klettner A, et al. Safety testing of indocyanine green with different surgical light sources and the protective effect of optical filters. Retina 2010;30:1685.
13. Klettner A, Koinzer S, Waetzig V, et al. Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. Cutan Ocul Toxicol 2010;29:122-9.
14. Klettner A, Möhle F, Lucius R, et al. Quantifying FITC-labeled latex beads opsonized with photoreceptor outer segment fragments; an easy and inexpensive method of investigating phagocytosis in the retinal pigment epithelium cells. Ophthalmic Res 2011;46:88-91.
15. Ammar DA, Mandava N, Kahook MY. The effects of aflibercept on the viability and metabolism of ocular cells in vitro. Retina 2013;33:1056-61.
16. Al-Hussaini H, Kam JH, Vugler A, et al. Mature retinal pigment epithelium cells are retained in the cell cycle and proliferate in vivo. Mol Vis 2008;14:1784-91.
17. Roider J, Michaud NA, Flotte TJ, et al. Response of the retinal pigment epithelium to selective photocoagulation. Arch Ophthalmol 1992;110:1786-92.
18. Treumer F, Klettner A, Baltz J, et al. Vectorial release of matrix metalloproteinases (MMPs) from porcine RPE-choroid explants following selective retina therapy (SRT): towards slowing the macular ageing process. Exp Eye Res 2012;97:63-72.
19. Julien S, Biesemeier A, Taubitz T, et al. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 2014;98:813-25.
20. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev 2005;85:845-81.
21. Nandrot EF, Dufour EM. Merkt in daily retinal phagocytosis: a history in the making. Adv Exp Med Biol 2010;664:133-40.
22. Mustafi D, Kevany BM, Genoud C, et al. Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration. FASEB J 2011;25:3157-76.
23. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
24. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121:150-61.
25. Lassoued W, Murphy D, Tsai J, et al. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther 2010;10:1326-33.
26. Cox D, Greenberg S. Phagocytic signaling strategies: Fc(gamma)receptor-mediated phagocytosis as a model system. Semin Immunol 2001;13:339-45.
27. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117:4619-28.